Parkinson’s Disease Drug Market Driven by Cell Therapy & Gene-Based Treatments | DataM Intelligence

The Parkinson’s therapeutics market will grow from USD 5.92 Bn in 2024 to USD 12.83 Bn by 2033 at 8.1% CAGR, driven by novel therapies and global investment.

TEXAS, TX, UNITED STATES, July 30, 2025 /EINPresswire.com/ -- Parkinson’s disease therapeutics encompass drugs, device-based delivery systems, and emerging gene- or cell-based interventions aimed at managing motor and non-motor symptoms. Based on DataM Intelligence analysis, the market reached approximately USD 5.92 billion in 2024 and is projected to soar to USD 12.83 billion by 2033, at a compound annual growth rate of around 8.1%. Growth drivers include an aging global population, rising disease prevalence, and intensified R&D into disease-modifying treatments.

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/parkinsons-disease-therapeutics-market

Parkinson’s Disease Therapeutics Market Segments

By Drug Class:
Levodopa/carbidopa remains the dominant segment, accounting for over 50% of global revenue due to its long-standing efficacy and affordability. Meanwhile, dopamine agonists are the fastest-growing class, recently bolstered by new approvals such as apomorphine infusion devices and D1/D5 selective agonists like tavapadon.

By Route of Administration:
Oral formulations continue to dominate (approximately 63–75% share) due to convenience and reimbursement coverage. However, subcutaneous and infusion therapies, offering continuous symptom control are expanding most rapidly with recent regulatory approvals.

Key Players & Pipeline Highlights in Parkinson’s Disease Therapeutics Market

Leading companies include AbbVie, Eisai, Novartis, Kyowa Kirin, Teva, Boehringer Ingelheim, Roche, and Acadia Pharmaceuticals.

Notable pipeline assets include:

• Tavapadon (Cerevel Therapeutics): A D1/D5 receptor partial agonist now completing Phase III trials for early-stage PD.
• Prasinezumab (Roche/Prothena): Anti-α synuclein monoclonal antibody entering Phase III for early PD, marking a shift toward disease-modifying treatments.
• NEULARK (Neuron23 Inc.): A brain-penetrant LRRK2 inhibitor currently in Phase II studies using digital biomarkers to improve precision in early-stage PD treatment.

Regional Market Dynamics

• North America dominates with roughly 40% of global market share in 2024, underpinned by high PD prevalence, strong diagnostics, and early adoption of advanced therapies including infusion systems and DBS.
• Europe contributes around 30%, supported by solid reimbursement frameworks, disease awareness, and robust access to both conventional and novel therapies (e.g., new delivery platforms).
• Asia Pacific (~18%) is the fastest-growing region, driven by aging demographics in China, India, and Japan, increasing diagnosis rates, and expanded telehealth access in rural areas.
• Middle East & Africa (~7%) are emerging markets, led by economic growth and improving access in GCC countries like Saudi Arabia and the UAE.
• Latin America (~5%) shows modest growth, primarily in Brazil and Argentina, with increased access to generics and rising public chronic disease strategies.

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=parkinsons-disease-therapeutics-market

Investments & Strategic Moves in Parkinson’s Disease Therapeutics Market

United States
• July 2024: Merz Therapeutics completed its acquisition of INBRIJA (levodopa inhalation) and FAMPYRA (dalfampridine) from Acorda, expanding its neurology portfolio.
• September 2024: AbbVie reported positive Phase III data from the TEMPO-1 trial of tavapadon as a monotherapy for early PD, highlighting its potential as a once-daily oral agent.

Japan
• 2025 (ongoing): Japan’s METI and health sectors continue to subsidize drug discovery ventures in dementia and neurodegeneration, including Parkinson’s candidates like Sumitomo Pharma’s DSP 1083 cellular medicine initiative.

Europe & Other Regions
• July 2024: The Michael J. Fox Foundation granted £4.7 million to Scottish-based Lario Therapeutics, supporting development of a calcium channel inhibitor targeting early PD progression.
• In Europe, Roche's advancement of prasinezumab into Phase III trials also catalyzes broader investment and academic engagement across Western neuroscience centers.

Parkinson’s Disease Therapeutics Market Trends & Emerging Opportunities

• Disease-Modifying Therapies: A shift toward α-synuclein-targeting antibodies and LRRK2 inhibitors promises to address progression, not just symptoms.
• Digital Biomarkers & Personalization: Tools like gait/speech analysis and AI-driven phenotyping are enhancing precision medicine approaches.
• New Delivery Formats: Continuous infusion pumps and inhaled levodopa offer better fluctuation control, supporting patient adherence.
• Combination Therapies: Multi-modal regimens integrating neuroprotective agents, lifestyle interventions, and device support signify holistic treatment models.

Parkinson’s Disease Therapeutics Market Challenges & Future Outlook

Challenges:

• High R&D Costs: Clinical development for novel biologics, gene therapies, or delivery devices remains expensive and lengthy.
• Regulatory Complexity: Approvals for infusions and disease-modifying therapies vary globally and require robust biomarker validation.
• Alternative Treatment Growth: Deep brain stimulation, physical therapy, and lifestyle interventions are reducing sole reliance on pharmaceuticals.

Future Outlook:

With its estimated near doubling by 2033, the Parkinson’s therapeutics market is entering a transformative era. Stakeholders aligning innovation in non-dopaminergic drugs, digital biomarkers, advanced delivery systems, and global partnerships particularly across North America, Europe, and Asia-Pacific stand to lead this highly competitive and life-changing field.

Unlock 360° Market Intelligence with 2 Days FREE Trial Access of DataM Subscription Now!: https://www.datamintelligence.com/reports-subscription

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Related Reports:
Alzheimer Drugs Market Size
Migraine Drugs Market Growth

Sai Kumar
DataM Intelligence 4market Research LLP
+1 877-441-4866
sai.k@datamintelligence.com
Visit us on social media:
LinkedIn
Twitter